All In Biotech

Drug Trial Radar · NCT03199872

RV001V, a RhoC Anticancer Vaccine, Against Metastasis From Solid Tumours

A Phase I/II Study of RV001V, a RhoC Anticancer Vaccine, Against Metastasis From Solid Tumours

Last checked: Nov 19, 2026Latest source record: Jun 9, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

22

Actual

Start

Mar 30, 2017

Primary completion

Aug 1, 2018

Study completion Mar 29, 2019

Sponsor

Lead sponsor
RhoVac APSIndustry
Sponsor type
Industry
Collaborators
Dantrials Aps
First posted
Jun 27, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Male only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The study will evaluate safety and immunological response to RhoC peptide vaccine in patients with prostate cancer

Conditions

  • Prostate Cancer

Interventions

  • RV001VBiological

    Sc injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportions of Participants With Treatment-related Adverse EventsTime frame: 8 month

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Rigshospitalet

    Copenhagen, Denmark

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.